The finding that HLA-E prevents the control of EBV-infected lymphoma cells via the stimulation of the inhibitory NKG2A receptor prompted us to test, whether the monoclonal antibody (mAB)-mediated blocking of NKG2A led to an effective control of EBV-infected tumor cells. The gene discussed is KLRC1; the disease is neoplasm.